KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Capital Expenditures readings, the most recent being $168.0 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 32.28% to $168.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $542.0 million, a 8.18% increase, with the full-year FY2025 number at $501.0 million, up 0.6% from a year prior.
  • Capital Expenditures hit $168.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from $142.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $168.0 million in Q1 2026 to a low of $96.0 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $129.0 million (2024), compared with a mean of $131.8 million.
  • Biggest five-year swings in Capital Expenditures: decreased 18.49% in 2024 and later surged 32.28% in 2026.
  • Teva Pharmaceutical Industries' Capital Expenditures stood at $142.0 million in 2022, then decreased by 16.2% to $119.0 million in 2023, then rose by 8.4% to $129.0 million in 2024, then increased by 10.08% to $142.0 million in 2025, then grew by 18.31% to $168.0 million in 2026.
  • The last three reported values for Capital Expenditures were $168.0 million (Q1 2026), $142.0 million (Q4 2025), and $136.0 million (Q3 2025) per Business Quant data.